Marianna Karewicz, APRN
Family · Honolulu, HINPI 1255609392
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,865 of the $2,893 with a category attached, or 64.5%. Novartis accounts for 74.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $2,500 and has fallen 84.8% since, to $380 in 2025.
Across 15 payments — averaging $192.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$171
- Galderma Laboratories, L.p.$135
- Pfizer$125
- LEO Pharma Inc.$124
- Boehringer Ingelheim$110
- plus $67 from 2 others
What the payments were for
- Travel & lodging$1,86564%
- Food & beverage$1,01535%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $2,161 |
| E.r. Squibb & Sons, L.L.C. | 2 | $171 |
| Galderma Laboratories, L.p. | 1 | $135 |
| Pfizer | 1 | $125 |
| LEO Pharma Inc. | 3 | $124 |
| Boehringer Ingelheim | 1 | $110 |
| Regeneron Healthcare Solutions, Inc. | 1 | $55 |
| Incyte Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,893 in reported general payments places this provider in the 85th percentile of 466 family providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 61 | $232,738 |
| Enbrel SureclickEtanercept | 12 | $91,302 |
| Dupixent SyringeDupilumab | 14 | $52,708 |
| Clobetasol Propionate | 123 | $8,366 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 64 | $3,956 |
| Clindamycin Phosphate | 72 | $3,364 |
| Ketoconazole | 144 | $2,849 |
| Ammonium Lactate | 89 | $2,301 |
| Hydrocortisone Valerate | 43 | $2,219 |
| Betamethasone Dipropionate | 37 | $1,844 |
| Tacrolimus | 15 | $1,804 |
| Doxycycline Hyclate | 47 | $1,274 |
| Desonide | 15 | $1,269 |
| Ciclopirox | 28 | $1,171 |
| Triamcinolone Acetonide | 96 | $1,161 |
Paid to pharmacies, not to this prescriber.
Other family in Honolulu
- Joey SesonHonolulu$48K
- Kanna DokgoHonolulu$26K
- John MosesHonolulu$24K
- Leif MarzHonolulu$11K
- Ia Lynne AranaHonolulu$9K
- Josette DudoitHonolulu$8K
- Kailie WongHonolulu$6K
- Jane StinsonHonolulu$6K
- Melissa leHonolulu$6K
- Karen RowanHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.